1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced

 
• By Derrick Gingery

US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.

Money Wave
Estimates of future BsUFA revenue indicate substantial increases compared to FY 2019 collections. • Source: Shutterstock

Biosimilar user fee collections missed estimates significantly once again in fiscal year 2019, which forced the US Food and Drug Administration to reduce spending to account for the shortfall.

BsUFA collections were nearly $4.2m less than estimates after fee-paying applications were 22% less than expected, the agency said in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.